|Bid||31.99 x 1300|
|Ask||32.05 x 300|
|Day's Range||31.97 - 32.28|
|52 Week Range||29.83 - 37.39|
|PE Ratio (TTM)||27.32|
|Dividend & Yield||1.28 (3.99%)|
|1y Target Est||N/A|
The U.S. Food and Drug Administration has already cleared 21 new prescription medicines for sale against 22 in the whole of 2016, and just nine at this stage last year. The European Medicines Agency has recommended 42 compared with a 2016 total of 81, and 31 in the first five months of last year. Unlike the FDA, the EMA includes generic or non-patented drugs in its list.
Remicade, a top-selling drugs for the treatment of inflammatory disorders, is losing market share after the loss of exclusivity in European markets in February 2015.
Combined sales for Januvia and Janumet were ~$1.3 billion for 1Q17, a ~5.0% fall from $1.4 billion in 1Q16.